Brexit: How Do Pharma Firms Plan For An Unknown Scenario?
Executive Summary
As the Brexit negotiations continue, the pharmaceutical industry is anxious to have a cut-off date when it should start taking action to deal with the legal repercussions of the UK becoming a third country within the context of the EU medicines network. There are no clear answers yet, and companies are being asked to continue to wait and watch.
You may also be interested in...
Betting On A Brexit Transition Period Is A Gamble: EMA Warning For Industry
A senior official at the European Medicines Agency has warned pharmaceutical companies are taking a risk by endlessly waiting to get news on whether there would be a Brexit transition period. Drug makers still waiting to prepare for changes that may be needed once the UK leaves the EU were told 'this is your risk and your decision.'
Lobbying Pays Off As UK Ministers Speak Out On Post-Brexit Regulatory Collaboration
Pressure from industry and other bodies seems to be paying off after two senior government ministers publicly called for a “close working relationship” between the UK and the EU after Brexit. The move has been welcomed by the life sciences industry, which has been lobbying for some sort of regulatory cooperation agreement to avoid regulatory divergence and possible delays to new product launches.
Brexit: Advising Companies To Prepare For Only The Worst Case Scenario Is Premature, Says BIA
The European Medicines Agency has issued figures on the number of UK-based sponsors of orphan medicines, and qualified persons for pharmacovigilance – both of which will be affected when the UK leaves the EU. However, UK BioIndustry Association thinks advising companies on changes they will have to make may be premature as it is yet to be decided what role, if any, the UK will have in the EU medicines network following Brexit.